CTX-112

Bengaluru-based NKure Therapeutics and CRISPR Therapeutics have formed a strategic partnership to co-develop CTX112, a next-generation allogeneic CAR-T therapy for B-cell malignancies in India.

Krystal Biotech reported a 473% increase in full-year revenue, driven by VYJUVEK sales, and anticipates European and Japanese regulatory decisions in 2025.

CRISPR Therapeutics presented encouraging Phase 1/2 data for CTX112, an allogeneic CAR T-cell therapy, at the ASH Annual Meeting.

CRISPR Therapeutics' stock has declined despite the FDA and EU approvals of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.

CRISPR Therapeutics' stock has declined despite FDA and EU approvals of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia.